2023 is shaping up to be a crucial year for everyone involved – and affected – by the pharmaceutical industry. It's likely to be a year of experimentation for payers – and defensiveness for drug makers.
The latest funding brings total investment in the company to $750 million. The money has gone, in part, toward licensing of promising drug candidates in breast, lung and other cancers.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
A forum convened by patient advocates will serve as the launching event for the ICER Watch patient portal, which will track the movements of the Institute for Clinical and Economic Review, which last month released a report on the effectiveness of treatment options for multiple myeloma.
Patient outcomes and the overall cost of cancer care matters more than the rising cost of individual drugs, argues Dr. Andrew Pecora, an oncologist who is rebutting the prevailing argument that cancer drugs are too expensive.
A smart inforgraphic from trade group California Association of Health Plans depicts how cancer drug costs have become exorbitant.
A top oncologist's criticisms of cancer drug costs seems to have hit a nerve among the scads of doctors and cancer execs at ASCO.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.